Vai al contenuto principale della pagina

Multimodality Treatments in Metastatic Gastric Cancer



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Petrillo Angelica Visualizza persona
Titolo: Multimodality Treatments in Metastatic Gastric Cancer Visualizza cluster
Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica: 1 online resource (162 p.)
Soggetto topico: Medicine
Soggetto non controllato: advanced gastric cancer
biomarkers
body composition
bone flare
CAR T cell therapy
cfDNA
circulating tumor cell
conversion surgery
ctDNA
epithelial-mesenchymal transition
Epstein Barr Virus
exome sequencing
formalin fixed paraffin embedded
gastric cancer
gastro-oesophageal cancer
hepatectomy
HER2-inhibition
immune checkpoint inhibitors
immunotherapy
liquid biopsy
liver metastasis
metastatic
metastatic gastric cancer
microsatellite instability
mutational concordance
n/a
new drug development
nutritional status
outcome
precision medicine
predictive biomarkers
RANK-L
resistance to treatment
response monitoring
sarcopenia
stage IV
stage iv gastric cancer
subcutaneous fat area
target therapy
toxicity
treatment
tumor mutational burden
vaccines
VEGFR-inhibition
visceral fat area
Persona (resp. second.): PetrilloAngelica
Sommario/riassunto: Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.
Titolo autorizzato: Multimodality Treatments in Metastatic Gastric Cancer  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910557390503321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui